Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN study

Hans Jürgen Stellbrink, Eric L E Fevre, Andrew Carr, Michael S. Saag, Geoffrey Mukwaya, Silvia Nozza, Srinivas Rao Valluri, Manoli Vourvahis, Alex R. Rinehart, Lynn Mcfadyen, Carl Fichtenbaum, Andrew Clark, Charles Craig, Annie F. Fang, Jayvant Heera

Research output: Contribution to journalArticle

Abstract

OBJECTIVE:: To evaluate the efficacy of maraviroc plus darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1–infected subjects. DESIGN:: MODERN was a multicenter, double-blind, non-inferiority, phase III study in HIV-1–infected, antiretroviral-naive adults with plasma HIV-1 RNA >1000?copies/mL and no evidence of reduced susceptibility to study drugs. METHODS:: At screening, participants were randomized 1:1 to undergo either genotypic or phenotypic tropism testing. Participants with CCR5-tropic HIV-1 were randomized 1:1 to receive maraviroc 150?mg once daily or tenofovir/emtricitabine once daily each with darunavir/ritonavir once daily for 96 weeks. The primary endpoint was the proportion of participants with HIV-1 RNA?

Original languageEnglish
JournalAIDS (London, England)
DOIs
Publication statusAccepted/In press - Feb 5 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN study'. Together they form a unique fingerprint.

  • Cite this

    Stellbrink, H. J., Fevre, E. L. E., Carr, A., Saag, M. S., Mukwaya, G., Nozza, S., Valluri, S. R., Vourvahis, M., Rinehart, A. R., Mcfadyen, L., Fichtenbaum, C., Clark, A., Craig, C., Fang, A. F., & Heera, J. (Accepted/In press). Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN study. AIDS (London, England). https://doi.org/10.1097/QAD.0000000000001058